Analyst Price Targets — PRCT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 2, 2026 8:06 pm | — | Truist Financial | $25.00 | $21.03 | TheFly | Procept BioRobotics downgraded to Hold from Buy at Truist |
| June 24, 2026 10:05 am | Vijay Kumar | Evercore ISI | $30.00 | $20.60 | TheFly | Procept BioRobotics initiated with an Outperform at Evercore ISI |
| June 11, 2026 10:06 am | — | Leerink Partners | $29.00 | $29.09 | TheFly | Procept BioRobotics downgraded to Market Perform from Outperform at Leerink |
| April 30, 2026 11:17 am | Matt O'Brien | Piper Sandler | $35.00 | $21.71 | TheFly | Procept BioRobotics price target raised to $35 from $28 at Piper Sandler |
| February 27, 2026 6:03 pm | Richard Newitter | Truist Financial | $30.00 | $22.69 | StreetInsider | Procept BioRobotics Corp (PRCT) PT Lowered to $30 at Truist Securities |
| February 26, 2026 10:58 am | Nathan Treybeck | Wells Fargo | $34.00 | $27.84 | StreetInsider | Procept BioRobotics Corp (PRCT) PT Lowered to $34 at Wells Fargo |
| December 18, 2025 2:14 pm | Richard Newitter | Truist Financial | $47.00 | $34.24 | TheFly | Procept BioRobotics price target lowered to $47 from $50 at Truist |
| December 12, 2025 5:57 am | Danielle Antalffy | UBS | $62.00 | $36.02 | StreetInsider | UBS Starts Procept BioRobotics Corp (PRCT) at Buy |
| December 2, 2025 11:34 am | Patrick Wood | Morgan Stanley | $51.00 | $30.41 | TheFly | Procept BioRobotics price target lowered to $51 from $56 at Morgan Stanley |
| November 5, 2025 2:23 pm | Matt O'Brien | Piper Sandler | $50.00 | $32.80 | TheFly | Procept BioRobotics price target lowered to $50 from $55 at Piper Sandler |
Latest News for PRCT
SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company's management will host a corresponding conference…
Pre-Market Stock Futures: Futures are trading higher after a dreadful day on Wall Street, when all the major indices traded lower, and we saw the same pattern that has developed over the last week. The "Buy the Dip" traders come in, briefly get an uptick, and a move higher, and the sellers swarm in to... Here Are Thursday's Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General…
SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation® therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus…
SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), which strengthen the recommendation for Aquablation therapy (Robotic Waterjet Treatment) as a surgical treatment option for men with…
PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRCT.
U.S. House Trading
No House trades found for PRCT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.